AJK BIOPHARMACEUTICAL LLC

Biotech · Private

Amphiphilic cyclic antimicrobial peptides (AMPs) targeting multidrug-resistant bacteria

Grants
$597K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria$300,000
Federal grantDepartment of Health and Human Services · Phase I · Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria$296,643
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3143Iria Pharma, LLC——
3144DINYA DNA INC—$3.8M
3145CARDIAC RSK3 INHIBITORS, LLC——
3146AJK BIOPHARMACEUTICAL LLC——
3147Kinetiq——
3148ExQor Technologies Inc——
3149Lung Biotechnology——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Amphiphilic Peptides For Nucleic Acid And Protein Deliveryapplication
  • Fatty Acyl And Fatty Ether Conjugates Of Remdesivir And Its Active Metabolites As Antiviralsapplication
  • Synthetic Antimicrobial Peptidesapplication
  • Amphiphilic Peptides For Nucleic Acid And Protein Deliveryapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.